BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11182633)

  • 1. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors.
    Bamberger AM; Milde-Langosch K; Schulte HM; Löning T
    Horm Res; 2000; 54(1):32-7. PubMed ID: 11182633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype.
    Bamberger AM; Methner C; Lisboa BW; Städtler C; Schulte HM; Löning T; Milde-Langosch K
    Int J Cancer; 1999 Oct; 84(5):533-8. PubMed ID: 10502734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
    Chu JS; Lee WJ; Chen KM; Hsu HC
    J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
    Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
    J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of quantitative analysis to biologic profile evaluation in breast cancer.
    Querzoli P; Ferretti S; Albonico G; Magri E; Scapoli D; Indelli M; Nenci I
    Cancer; 1995 Dec; 76(12):2510-7. PubMed ID: 8625078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors].
    Sundblad AS; Caprarulo L
    Medicina (B Aires); 1996; 56(6):683-9. PubMed ID: 9284572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
    Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
    Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status.
    Kappes H; Goemann C; Bamberger AM; Löning T; Milde-Langosch K
    Pathobiology; 2001; 69(3):136-42. PubMed ID: 11872959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
    Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
    Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays.
    Bae YK; Gong G; Kang J; Lee A; Cho EY; Lee JS; Suh KS; Lee DW
    Am J Surg Pathol; 2012 Dec; 36(12):1817-25. PubMed ID: 23154769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
    Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
    Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of activator protein-1 (AP-1) family members in breast cancer.
    Kharman-Biz A; Gao H; Ghiasvand R; Zhao C; Zendehdel K; Dahlman-Wright K
    BMC Cancer; 2013 Sep; 13():441. PubMed ID: 24073962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
    Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
    Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
    J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.